RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Freeline Therapeutics Holdings Stock

Freeline Therapeutics Holdings ROE 2024

Freeline Therapeutics Holdings ROE

-1.7

Ticker

FRLN

ISIN

US35655L1070

WKN

A2QADU

In 2024, Freeline Therapeutics Holdings's return on equity (ROE) was -1.7, a 45.61% increase from the -1.17 ROE in the previous year.

Freeline Therapeutics Holdings Aktienanalyse

What does Freeline Therapeutics Holdings do?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Freeline Therapeutics Holdings's Return on Equity (ROE)

Freeline Therapeutics Holdings's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Freeline Therapeutics Holdings's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Freeline Therapeutics Holdings's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Freeline Therapeutics Holdings’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Freeline Therapeutics Holdings stock

What is the ROE (Return on Equity) of Freeline Therapeutics Holdings this year?

The ROE of Freeline Therapeutics Holdings this year is -1.7 undefined.

How has the Return on Equity (ROE) of Freeline Therapeutics Holdings developed compared to the previous year?

The ROE of Freeline Therapeutics Holdings has increased by 45.61% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Freeline Therapeutics Holdings?

A high ROE indicates that Freeline Therapeutics Holdings generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Freeline Therapeutics Holdings?

A low ROE can indicate that Freeline Therapeutics Holdings is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Freeline Therapeutics Holdings affect the company?

A change in ROE (Return on Equity) of Freeline Therapeutics Holdings can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Freeline Therapeutics Holdings?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Freeline Therapeutics Holdings?

Some factors that can influence Freeline Therapeutics Holdings's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Freeline Therapeutics Holdings pay?

Over the past 12 months, Freeline Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Freeline Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Freeline Therapeutics Holdings?

The current dividend yield of Freeline Therapeutics Holdings is .

When does Freeline Therapeutics Holdings pay dividends?

Freeline Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Freeline Therapeutics Holdings?

Freeline Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Freeline Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Freeline Therapeutics Holdings located?

Freeline Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Freeline Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Freeline Therapeutics Holdings from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Freeline Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Freeline Therapeutics Holdings in the year 2023?

In the year 2023, Freeline Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Freeline Therapeutics Holdings pay out the dividend?

The dividends of Freeline Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Freeline Therapeutics Holdings

Our stock analysis for Freeline Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Freeline Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.